Eden Kleiman, Linda Liang, Elizabeth Epps, Jared Gunn, Mingfa Zang, Marrit Putker, Ludovic Bourre and Pirouz Daftarian
Crown Bioscience, Inc., 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127
JSR Life Sciences, Sunnyvale, California
This research describes a study in which the previously reported in vitro T cell exhaustion model was employed to test a novel inhibitor of SMARCA4/2 ATPase activity, FHT-1015.
CD3+ T cells were isolated from 2 healthy donor PBMC collections. Purified T cells were stimulated with Dynabeads 4x times at 48-hour intervals. Cells were treated additionally with DMSO every 48 hours (4x DMSO), 1x to 4x times with 100nM FHT-1015 (SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor) every 48 hours or left untreated. On day 8, medium was collected for cytokine analysis, and T cells were immunophenotyped by flow cytometry for co-inhibitory receptor expression.